Anti-Benralizumab Antibodies

s

s

s

Antibodies for bioanalysis and drug monitoring of benralizumab and biosimilars

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug benralizumab (Fasenra®) using our range of ready-made anti-idiotypic antibodies.

• Highly specific to benralizumab and the benralizumab/IL5Rα complex
• Fully human surrogate positive control or calibrator
• Sequence defined, well characterized reagents with secure supply
• Recombinant production, stringent quality control for batch-to-batch consistency
• Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Benralizumab.

* Affinity measured in the monovalent Fab format.
¹ Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
² Fab2-FH-X22-HRP = Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP-conjugated BiCatcher.
³ Fab-FH-X22-HRP = Monovalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP-conjugated SpyCatcher.

Anti-Benralizumab Inhibitory Antibodies (Type 1)

Type 1 anti-benralizumab antibodies inhibit the binding of the drug benralizumab to its target, interleukin-5 receptor alpha (IL5Rα). They are ideal for the development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format, they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

Anti-Benralizumab IL5Rα Complex Specific Antibodies (Type 3)

The Type 3 antibodies specifically recognize the drug-target complex, detecting benralizumab only when it is bound to IL5Rα. They are suitable as a detection antibody in a PK antigen capture assay.

ELISA Protocols to Get You Started

PK Bridging ELISA

Fig. 1. Benralizumab PK bridging ELISA using antibodies TZA068 (capture) and TZA069P (detection).

Schematic image of PK bridging ELISA detecting free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple), labeled with HRP.

PK Antigen Capture ELISA

Fig. 2. Benralizumab PK antigen capture ELISA using IL5Rα and TZA097P.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), labeled with HRP.

ADA Bridging ELISA

Fig. 3. Benralizumab ADA bridging ELISA using antibodies HCA426, HCA427, and HCA428.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Resources

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.